greeksoup/ stock research

PAVmed (PAVM) Q3 FY2026 earnings: revenue $41,000, up 720.0% on the year

PAVmed Inc. (PAVM) reported revenue of $41,000 for Q3 FY2026, the quarter ended 30 September 2026, up 720.0% on the same quarter a year earlier. Net income was -$12 million, and diluted earnings per share $-1.77. The figures are the company's own, from the 10-Q it filed with the SEC on 16 November 2026.

Revenue
$41,000
+720.0% on the year · +24.2% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
-16407.3%
-96880.0% a year earlier
Q4 FY2024Q3 FY2026
Net income
-$12 million
Q4 FY2024Q3 FY2026
Diluted EPS
-$1.77
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 kept.

  • Non-GAAP adjusted loss per share: Non-GAAP adjusted net loss was about $1.2 million, or $(0.19) per share, against $(0.27) in 2Q26 and $(0.62) in 3Q25. The measure excludes stock-based and other non-cash items.
  • Medicare payments began in October: Lucid began receiving Medicare payments in October. Claims for its Texas laboratory go to Novitas, the MAC, and are paid at the established Clinical Laboratory Fee Schedule rate.
  • Test volume and revenue in 3Q26: The company performed 2,871 EsoGuard tests and recognized $1.2 million of revenue in 3Q26, against 2,770 tests and $1.5 million of revenue in 2Q26.
Read the earnings call summary

Income statement (profit and loss)

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Revenue0.00.00.0+24.2%+720.0%
Cost of revenue0.20.10.1+29.5%+187.3%
Gross profit-0.1-0.1-0.1
Gross margin-285.4%-269.7%-1000.0%
Research and development1.92.11.1-7.0%+76.7%
Operating income-6.7-7.0-4.8
Operating margin-16407.3%-21278.8%-96880.0%
Interest expense0.00.00.0+150.0%-37.5%
Pre-tax income-13.0-6.6-6.0
Income tax0.00.00.0
Net income-11.7-5.4-5.4
Net margin-28426.8%-16315.2%-107660.0%
Diluted EPS-$1.77 basic-$0.87-$2.17
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Operating cash flow2.4-2.7-0.9
Capital expenditure0.00.00.0-38.5%+166.7%
Free cash flow2.4-2.7-0.9
Free cash flow margin5870.7%-8109.1%-17980.0%
Cash from investing-0.0-0.0-0.0
Cash from financing2.70.0-0.0
Depreciation and amortisation0.00.00.00.0%-13.6%
Share-based compensation1.00.90.4+5.5%+152.5%
Diluted shares, weighted7m6m3m+5.9%+131.0%
Shares outstanding at period end7m6m3m+10.8%+125.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Shareholders' equity27.535.032.5-21.7%-15.6%
Non-controlling interest-17.3-15.7-10.0
Redeemable equityn/an/a3.3
Debt15.015.06.90.0%+117.4%
Operating lease liabilities1.31.41.8-7.9%-29.3%
Other liabilities8.84.53.6+95.1%+147.1%
Total liabilities and equity35.240.238.1-12.5%-7.5%
Fixed assets0.10.10.1-15.1%-23.5%
Cash and equivalents3.63.83.1-3.9%+17.1%
Receivables0.00.00.0+93.8%+933.3%
Other assets31.536.334.9-13.4%-9.8%
Total assets35.240.238.1-12.5%-7.5%

Questions

What was PAVmed's revenue in Q3 FY2026?

PAVmed (PAVM) reported revenue of $41,000 for Q3 FY2026, the quarter ended 30 September 2026, up 720.0% on the same quarter a year earlier.

How much did PAVmed earn in Q3 FY2026?

Net loss for Q3 FY2026 was $12 million, and the diluted loss per share $1.77.

When did PAVmed report Q3 FY2026 results?

PAVmed filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 16 November 2026.

Quarterly results, the last 20 quarters

Q3 FY2021Q1 FY2022 †Q2 FY2022 *Q3 FY2022 †Q4 FY2022 *Q1 FY2023 †Q2 FY2023Q3 FY2023Q4 FY2023 * †Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue0.20.20.00.10.10.40.20.81.01.01.01.00.00.00.00.00.10.00.00.0
Cost of revenue0.10.40.01.61.61.31.71.81.61.71.71.40.00.00.00.10.10.10.10.2
Gross profit0.1-0.20.0-1.6-1.5-0.9-1.5-1.0-0.6-0.7-0.7-0.4-0.0-0.0-0.0-0.1-0.0-0.1-0.1-0.1
Gross margin28%-95%n/a-2039%-1346%-202%-915%-125%-53%-74%-67%-38%n/a-350%-583%-1000%-65%-341%-270%-285%
R&D5.35.96.76.26.74.03.53.23.61.91.61.50.80.80.81.11.81.42.11.9
Operating income-13.7-19.6-23.5-23.4-24.7-20.4-16.5-15.5-16.4-14.0-13.7-11.6-5.2-5.4-4.7-4.8-6.8-8.0-7.0-6.7
Operating margin-6834%-10389%n/a-30746%-22033%-4574%-9930%-1963%-1562%-1404%-1368%-1158%n/a-68075%-78583%-96880%-13079%-36523%-21279%-16407%
Interest expensen/an/a0.50.5n/a0.20.20.20.00.00.00.00.00.00.00.00.00.00.00.0
Pre-tax income-13.7-19.6-29.1-29.9-24.6-22.2-17.9-21.8-17.4-18.5-14.960.71.118.6-12.3-6.0-2.8-1.1-6.6-13.0
Tax raten/an/an/an/an/an/an/an/an/an/an/an/an/a0%n/an/an/an/an/an/a
Net income-12.2-16.9-25.5-26.1-20.5-17.9-14.5-17.7-14.0-15.2-10.864.41.419.0-11.9-5.4-1.3-0.1-5.4-11.7
Net margin-6114%-8927%n/a-34376%-18268%-4020%-8757%-2234%-1338%-1521%-1083%6440%n/a237100%-198683%-107660%-2429%-273%-16315%-28427%
Diluted EPS-$16.88-$22.50 basic-$32.63-$32.63n/a-$20.85-$15.75-$18.00n/a-$19.65-$8.93$10.80$0.90$2.55-$5.55-$2.17-$0.51-$1.10-$0.87-$1.77 basic
Operating cash flow-8.0-12.3-22.6-19.3-16.8-16.4-12.8-11.1-11.9-13.1-11.7-8.90.1-1.6-1.2-0.9-1.6-2.6-2.72.4
Capital expenditure0.00.60.40.30.30.00.00.00.20.00.00.00.00.00.00.00.00.00.00.0
Free cash flow-8.1-12.8-22.9-19.7-17.1-16.4-12.8-11.1-12.1-13.2-11.7-8.90.1-1.6-1.2-0.9-1.6-2.6-2.72.4
Shares outstanding750,226772,544773,536819,808840,08913m964,7771m1m1m1m1m1m2m3m3m4m25m6m7m
Filing10-Q10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 16 November 2026: the filing.